What is Spinogenix?
Spinogenix is dedicated to pioneering innovative treatments for a spectrum of neurological and psychiatric disorders. The company's core research centers on regenerative small molecule drugs designed to enhance synaptic function. These therapies aim to address critical unmet needs in conditions such as Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), schizophrenia, and related cognitive and motor impairments. The company's approach represents a significant advancement in the field of neurodegenerative disease treatment.
How much funding has Spinogenix raised?
Spinogenix has raised a total of $10.6M across 1 funding round:
Private Equity
$10.6M
Private Equity (2026): $10.6M, investors not publicly disclosed
What's next for Spinogenix?
With the recent major strategic investment, Spinogenix is poised to advance its pipeline of regenerative therapies. The substantial capital infusion is anticipated to fuel further clinical development, potentially enabling the company to move its promising drug candidates through later-stage trials. This strategic financing will likely bolster Spinogenix's research and development capabilities, positioning it for future growth and potential market entry in the highly competitive biopharmaceutical landscape. The company's focus on restoring brain synapses marks a critical area for future therapeutic innovation.
See full Spinogenix company page
